Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 3;59(6):2204-2210.
doi: 10.1002/anie.201913125. Epub 2019 Dec 17.

The 3F Library: Fluorinated Fsp3 -Rich Fragments for Expeditious 19 F NMR Based Screening

Affiliations

The 3F Library: Fluorinated Fsp3 -Rich Fragments for Expeditious 19 F NMR Based Screening

Nikolaj S Troelsen et al. Angew Chem Int Ed Engl. .

Abstract

Fragment-based drug discovery (FBDD) is a popular method in academia and the pharmaceutical industry for the discovery of early lead candidates. Despite its wide-spread use, the approach still suffers from laborious screening workflows and a limited diversity in the fragments applied. Presented here is the design, synthesis, and biological evaluation of the first fragment library specifically tailored to tackle both these challenges. The 3F library of 115 fluorinated, Fsp3 -rich fragments is shape diverse and natural-product-like with desirable physicochemical properties. The library is perfectly suited for rapid and efficient screening by NMR spectroscopy in a two-stage workflow of 19 F NMR and subsequent 1 H NMR methods. Hits against four diverse protein targets are widely distributed among the fragment scaffolds in the 3F library and a 67 % validation rate was achieved using secondary assays. This collection is the first synthetic fragment library tailor-made for 19 F NMR screening and the results demonstrate that the approach should find broad application in the FBDD community.

Keywords: NMR spectroscopy; drug discovery; fluorine; molecular diversity; synthesis design.

PubMed Disclaimer

References

    1. D. A. Erlanson, S. W. Fesik, R. E. Hubbard, W. Jahnke, H. Jhoti, Nat. Rev. Drug Discovery 2016, 15, 605-619.
    1. M. M. Hann, A. R. Leach, G. Harper, J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
    1. M. J. Harner, A. O. Frank, S. W. Fesik, J. Biomol. NMR 2013, 56, 65-75.
    1. C. A. Lepre in Methods in Enzymology (Eds.: J. N. Abelson, M. I. Simon), Elsevier, San Diego, 2011, pp. 220-239.
    1. C. Dalvit, A. Vulpetti, J. Med. Chem. 2019, 62, 2218-2244.

Publication types

MeSH terms

Substances

LinkOut - more resources